Detailed Coverage

Anthem Biosciences Q1FY27 Results: Revenue Slips, Margins Improve

Revenue from operations: ₹4,182 Mn
Profit after tax (PAT): ₹1,199 Mn

Reader Takeaway: Revenue decline driven by delivery timing, but margins and cash position remain strong.

What just happened

Anthem Biosciences reported a 22.6% year-on-year decline in consolidated revenue from operations for the first quarter of FY27, reaching ₹4,182 Mn. The CRDMO segment, the largest contributor, saw a 24.7% drop in revenue to ₹3,408 Mn, while Specialty Ingredients revenue fell by 11.5% to ₹774 Mn.

Why this matters

Despite the revenue shortfall, the company managed to improve its EBITDA margin by 153 basis points to 39.6% in Q1FY27 compared to Q1FY26. Profit after tax (PAT) stood at ₹1,199 Mn, with a PAT margin of 27.1%. The company also significantly increased its net cash position to ₹17,197 Mn from ₹7,848 Mn in the previous year.

The backstory

This marks a challenging start to the fiscal year for Anthem Biosciences, contrasting with its historical performance. The company operates in the CRDMO and Specialty Ingredients sectors, which are subject to delivery schedules and customer demand.

What changes now

Management attributes the revenue dip to timing shifts in deliveries to key clients. They expect scheduled deliveries to concentrate in the latter half of the fiscal year, aiming to regain momentum. The company is focused on maintaining revenue growth aligned with its past performance.

Risks to watch

The primary concern is revenue volatility. The 22.6% year-on-year decline requires monitoring to see if the 'timing shifts' cited by management translate into revenue recovery in subsequent quarters. Investors will be watching the second half of the financial year closely.

Peer comparison

(No specific peer data available in the filing)

Context metrics (time-bound)

• Revenue from Operations: ₹4,182 Mn in Q1FY27 (down 22.6% YoY).
• CRDMO Revenue: ₹3,408 Mn in Q1FY27 (down 24.7% YoY).
• Specialty Ingredients Revenue: ₹774 Mn in Q1FY27 (down 11.5% YoY).
• EBITDA Margin: 39.6% in Q1FY27 (up 153 bps YoY).
• PAT: ₹1,199 Mn in Q1FY27 (down 11.7% YoY).
• Net Cash: ₹17,197 Mn as of June 30, 2026 (up from ₹7,848 Mn on June 30, 2025).

What to track next

Investors should monitor the revenue performance in Q2FY27 and subsequent quarters to assess the impact of the expected delivery concentration in the latter half of the financial year. The company's ability to meet its historical growth trajectory will be a key factor.